2026³â 04¿ù 06ÀÏ ¿ù¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Medisca Takes Steps to Protect its Innovative Technologies

Medisca sues Fagron, HiperScan, and Gako for patent infringement
´º½ºÀÏÀÚ: 2023-09-27

MONTREAL-- September 27, 2023 -- Through decades of strategic research and development (“R&D”) investment, the Medisca name has become synonymous with innovative, customer-focused technologies. In compounding, for example, Medisca continues to deliver customized solutions with an unwavering commitment to quality and innovation. This includes the industry-leading Medisca MAZ™ Mixer, a compounding technology pioneered by the company following years of research and testing. The Medisca MAZ Mixer provides an efficient, uniform, high-quality solution for compounding hundreds of formulations.

So that it may continue to provide the innovations the industry wants and needs, Medisca complements its investment in R&D with a robust intellectual property (“IP”) portfolio. This includes patents in the U.S., Europe, Canada, and Australia. For years, Medisca has taken steps to inform the industry about its patent portfolio, including those related to the pioneering Medisca MAZ Mixer. A few companies, unfortunately, have decided to offer products that infringe on Medisca IP.

To protect its valuable rights and ensure that companies compete fairly, Medisca intends to protect its proprietary technologies against competitors’ infringing activities. That global enforcement effort began today with Medisca filing suits against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of patent number 3,538,071, belonging to the German counterpart of Medisca. The lawsuit was filed in the Munich district court of Germany and requests, as relief, an injunction and monetary remedies.

“With a deep respect for innovation and a responsibility to protect our intellectual property, we find it necessary to take legal action against this patent infringement,” said Panagiota Danopoulos, SVP of Global Strategy & Innovation at Medisca. “We believe in a fair and competitive marketplace, where innovation thrives, and this lawsuit reinforces our commitment to upholding these principles while defending our innovative spirit.”

Medisca hopes today’s filing will remind all competitors of the importance of respecting intellectual property belonging to the company. The compounding industry (e.g., pharmaceutical and CBD) has come to rely on the quality and efficiency offered by the Medisca MAZ Mixer. The industry must be able to continue to trust in these products and the unparalleled customer service and problem-solving innovations offered by Medisca.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Svante Acquires Carbon Dioxide Removal Project Developer, Carbon Alpha Corp.
Xsolla Announces Reseller Program to Help Game Developers Unlock New Revenue Streams in Local Markets
US PC Market Returned to 3% Growth in Q4 2025 as Windows 11 Refresh and Component Cost Increases Converged
Black Hat Asia 2026: Journalist and Security CEO Reveal Autonomous Cyber Threats Impacting APAC
Linnea Achieves CEP Certification for Cannabidiol Isolate
Radian Arc, VNPT and Blacknut Launch GPU Infrastructure in Vietnam, Enabling Cloud Gaming and AI Services
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services

 

India: The Up-and-Coming Solar Market
LG Electronics Presents Complete HVAC Solution Lineup Tailored for Eur...
Xsolla expands payment coverage in 18 markets with 6 local methods, he...
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women¡¯s Hea...
YouTube Expected to Approach 3 Billion Global Users by 2027 as Netflix...
ePLDT Group Powers Enterprise Transformation, Customer-Centric Innovat...
Takeda, Protagonist: FDA Accepts NDA, Grants Priority Review for Rusfe...

 


°øÁö»çÇ×
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ÃÁö'
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬银öõ(ÜÄÒ¬ÜØ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..